Enrichment of fluoroquinolone-resistant Staphylococcus aureus: Oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 1924-1928

  Firsov, Alexander A ^a   Lubenko, Irene Y ^a,b   Smirnova, Maria V ^a   Strukova, Elena N ^a   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MUTATION; FLUOROQUINOLONE RESISTANT STAPHYLOCOCCUS AUREUS; GENE AMPLIFICATION; GENETIC RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; MUTANT SELECTION WINDOW; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; SELECTION (GENETICS); STAPHYLOCOCCUS AUREUS;

EID: 44449122254     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01371-07     Document Type: Article

References (16)

1. Campion, J. J., P. J. McNamara, and M. E. Evans. 2004. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob. Agents Chemother. 48:4733-4744.
2. Firsov, A., I. Lubenko, M. Smirnova, E. Strukova, and S. Zinner. 2008. Heterogeneity of the mutant selection window: selection of resistant Staph ylococcus aureus at ciprofloxacin constant concentrations simulated close to the MIC or the mutant prevention concentration. Clin. Microbiol. Infect. 14(Suppl. 7):S674.
3. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
4. Firsov, A. A., A. A. Shevchenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter-and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665.
5. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
6. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, A. P. Arzamastsev, Y. A. Portnoy, and S. H. Zinner. 2004. ABT-492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J. Antimicrob. Chemother. 54:178-186.
7. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, S. H. Zinner, and Y. A. Portnoy. 2004. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int. J. Antimicrob. Agents 23:60-66.
8. Firsov, A. A., M. V. Smirnova, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner. 2006. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother. 58:1185-1192.
9. Firsov, A. A., S. H. Zinner, and I. Y. Lubenko. 2007. In vitro dynamic models as tools to predict antibiotic pharmacodynamics, p. 45-78. In C. H. Nightingale, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare USA, Inc., New York, NY.
10. MacGowan, A. P., and K. E. Bowker. 2003. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1096-1100.
11. MacGowan, A. P., C. A. Rogers, H. A. Holt, and K. E. Bowker. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
12. Olofsson, S. K., L. L. Marcusson, P. Komp Lindgren, D. Hughes, and O. Cars. 2006. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57:1116-1121.
13. Wilson, A. P. R., and R. N. Grüneberg. 1997. Ciprofloxacin: 10 years of clinical experience. Maxim Medical, Oxford, United Kingdom.
14. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33:147-156.
15. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.
16. Zinner, S. H., I. Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 52:616-622.